Home > Insider Trading > Filing (0000899243-15-000203)

Filing Details

Accession Number:: 0000899243-15-000203
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-07-02 18:00:40
Reporting Period:: 2015-07-02

Filing Date:: 2015-07-02
Accepted Time:: 2015-07-02 18:00:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1594864	Juno Therapeutics Inc.	JUNO	Biological Products, (No Disgnostic Substances) (2836)	463656275

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1281933	K Douglas Bratton	201 Main Street, Suite 1900 Fort Worth TX 76102		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-07-02	40,000	$54.75	182,669	No	4	S	Indirect	By JT Line Partners LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By JT Line Partners LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	25,766,130	Indirect	By CL Alaska, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares reported as sold on July 2, 2015 were sold in multiple transactions at prices ranging from a low of $54.00 per share to a high of $55.64 per share. The reporting person undertakes to provide to Juno Therapeutics, Inc. ("Issuer"), any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth above.
The shares of the Issuer reported in Column 5 are held directly by JT Line Partners LP ("JT"). The general partner of JT is Bratton Capital Management L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. JT is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of the shares of the Issuer held by JT, as well as a partial pecuniary interest in such shares. JT directly beneficially owns these shares of the Issuer. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to indirectly beneficially own the shares of the Issuer held by JT. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.
These 25,766,130 shares of the Issuer are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer, as well as a partial pecuniary interest in the shares held by CLA. Mr. Bratton does not intend to sell shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015. CLA may be deemed to directly beneficially own all of these shares of the Issuer.
(Continued from Footnote 3) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.